

# Primary Biliary Cholangitis Treatment Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

<https://marketpublishers.com/r/PD83E9FAFEC2EN.html>

Date: February 2021

Pages: 99

Price: US\$ 3,000.00 (Single User License)

ID: PD83E9FAFEC2EN

## Abstracts

### SUMMARY

Further key aspects of the report indicate that:

Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology

Chapter 2: Global Industry Summary

Chapter 3: Market Dynamics

Chapter 4: Global Market Segmentation by region, type and End-Use

Chapter 5: North America Market Segmentation by region, type and End-Use

Chapter 6: Europe Market Segmentation by region, type and End-Use

Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use

Chapter 8: South America Market Segmentation by region, type and End-Use

Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.

Chapter 10: Market Competition by Companies

Chapter 11: Market forecast and environment forecast.

Chapter 12: Industry Summary.

The global Primary Biliary Cholangitis Treatment market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.

Based on the type of product, the global Primary Biliary Cholangitis Treatment market segmented into

Ursodeoxycholic Acid (UDCA)

Obeticholic Acid (Ocaliva)

Based on the end-use, the global Primary Biliary Cholangitis Treatment market classified into

Hospitals

Clinics

Others

Based on geography, the global Primary Biliary Cholangitis Treatment market segmented into

North America [U.S., Canada, Mexico]

Europe [Germany, UK, France, Italy, Rest of Europe]

Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]

South America [Brazil, Argentina, Rest of Latin America]

Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]

And the major players included in the report are

Novartis

Bristol-Myers Squibb

Pfizer

GlaxoSmithKline

Teva Pharmaceutical

Retrophin

Lumena Pharmaceuticals

Intercept Pharmaceuticals

## Contents

### **1 RESEARCH SCOPE**

- 1.1 Research Product Definition
- 1.2 Research Segmentation
  - 1.2.1 Product Type
  - 1.2.2 Main product Type of Major Players
- 1.3 Demand Overview
- 1.4 Research Methodology

### **2 GLOBAL PRIMARY BILIARY CHOLANGITIS TREATMENT INDUSTRY**

- 2.1 Summary about Primary Biliary Cholangitis Treatment Industry
- 2.2 Primary Biliary Cholangitis Treatment Market Trends
  - 2.2.1 Primary Biliary Cholangitis Treatment Production & Consumption Trends
  - 2.2.2 Primary Biliary Cholangitis Treatment Demand Structure Trends
- 2.3 Primary Biliary Cholangitis Treatment Cost & Price

### **3 MARKET DYNAMICS**

- 3.1 Manufacturing & Purchasing Behavior in 2020
- 3.2 Market Development under the Impact of COVID-19
  - 3.2.1 Drivers
  - 3.2.2 Restraints
  - 3.2.3 Opportunity
  - 3.2.4 Risk

### **4 GLOBAL MARKET SEGMENTATION**

- 4.1 Region Segmentation (2017 to 2021f)
  - 4.1.1 North America (U.S., Canada and Mexico)
  - 4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
  - 4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
  - 4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
  - 4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
- 4.2 Product Type Segmentation (2017 to 2021f)

- 4.2.1 Ursodeoxycholic Acid (UDCA)
- 4.2.2 Obeticholic Acid (Ocaliva)
- 4.3 Consumption Segmentation (2017 to 2021f)
  - 4.3.1 Hospitals
  - 4.3.2 Clinics
  - 4.3.3 Others

## **5 NORTH AMERICA MARKET SEGMENT**

- 5.1 Region Segmentation (2017 to 2021f)
  - 5.1.1 U.S.
  - 5.1.2 Canada
  - 5.1.3 Mexico
- 5.2 Product Type Segmentation (2017 to 2021f)
  - 5.2.1 Ursodeoxycholic Acid (UDCA)
  - 5.2.2 Obeticholic Acid (Ocaliva)
- 5.3 Consumption Segmentation (2017 to 2021f)
  - 5.3.1 Hospitals
  - 5.3.2 Clinics
  - 5.3.3 Others
- 5.4 Impact of COVID-19 in North America

## **6 EUROPE MARKET SEGMENTATION**

- 6.1 Region Segmentation (2017 to 2021f)
  - 6.1.1 Germany
  - 6.1.2 UK
  - 6.1.3 France
  - 6.1.4 Italy
  - 6.1.5 Rest of Europe
- 6.2 Product Type Segmentation (2017 to 2021f)
  - 6.2.1 Ursodeoxycholic Acid (UDCA)
  - 6.2.2 Obeticholic Acid (Ocaliva)
- 6.3 Consumption Segmentation (2017 to 2021f)
  - 6.3.1 Hospitals
  - 6.3.2 Clinics
  - 6.3.3 Others
- 6.4 Impact of COVID-19 in Europe

## **7 ASIA-PACIFIC MARKET SEGMENTATION**

- 7.1 Region Segmentation (2017 to 2021f)
  - 7.1.1 China
  - 7.1.2 India
  - 7.1.3 Japan
  - 7.1.4 South Korea
  - 7.1.5 Southeast Asia
  - 7.1.6 Australia
  - 7.1.7 Rest of Asia Pacific
- 7.2 Product Type Segmentation (2017 to 2021f)
  - 7.2.1 Ursodeoxycholic Acid (UDCA)
  - 7.2.2 Obeticholic Acid (Ocaliva)
- 7.3 Consumption Segmentation (2017 to 2021f)
  - 7.3.1 Hospitals
  - 7.3.2 Clinics
  - 7.3.3 Others
- 7.4 Impact of COVID-19 in Europe

## **8 SOUTH AMERICA MARKET SEGMENTATION**

- 8.1 Region Segmentation (2017 to 2021f)
  - 8.1.1 Brazil
  - 8.1.2 Argentina
  - 8.1.3 Rest of Latin America
- 8.2 Product Type Segmentation (2017 to 2021f)
  - 8.2.1 Ursodeoxycholic Acid (UDCA)
  - 8.2.2 Obeticholic Acid (Ocaliva)
- 8.3 Consumption Segmentation (2017 to 2021f)
  - 8.3.1 Hospitals
  - 8.3.2 Clinics
  - 8.3.3 Others
- 8.4 Impact of COVID-19 in Europe

## **9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION**

- 9.1 Region Segmentation (2017 to 2021f)
  - 9.1.1 GCC
  - 9.1.2 North Africa

- 9.1.3 South Africa
- 9.1.4 Rest of Middle East and Africa
- 9.2 Product Type Segmentation (2017 to 2021f)
  - 9.2.1 Ursodeoxycholic Acid (UDCA)
  - 9.2.2 Obeticholic Acid (Ocaliva)
- 9.3 Consumption Segmentation (2017 to 2021f)
  - 9.3.1 Hospitals
  - 9.3.2 Clinics
  - 9.3.3 Others
- 9.4 Impact of COVID-19 in Europe

## **10 COMPETITION OF MAJOR PLAYERS**

- 10.1 Brief Introduction of Major Players
  - 10.1.1 Novartis
  - 10.1.2 Bristol-Myers Squibb
  - 10.1.3 Pfizer
  - 10.1.4 GlaxoSmithKline
  - 10.1.5 Teva Pharmaceutical
  - 10.1.6 Retrophin
  - 10.1.7 Lumena Pharmaceuticals
  - 10.1.8 Intercept Pharmaceuticals
- 10.2 Primary Biliary Cholangitis Treatment Sales Date of Major Players (2017-2020e)
  - 10.2.1 Novartis
  - 10.2.2 Bristol-Myers Squibb
  - 10.2.3 Pfizer
  - 10.2.4 GlaxoSmithKline
  - 10.2.5 Teva Pharmaceutical
  - 10.2.6 Retrophin
  - 10.2.7 Lumena Pharmaceuticals
  - 10.2.8 Intercept Pharmaceuticals
- 10.3 Market Distribution of Major Players
- 10.4 Global Competition Segmentation

## **11 MARKET FORECAST**

- 11.1 Forecast by Region
- 11.2 Forecast by Demand
- 11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

## **12 REPORT SUMMARY STATEMENT**



## List Of Tables

### LIST OF TABLES

1. Table Primary Biliary Cholangitis Treatment Product Type Overview
2. Table Primary Biliary Cholangitis Treatment Product Type Market Share List
3. Table Primary Biliary Cholangitis Treatment Product Type of Major Players
4. Table Brief Introduction of Novartis
5. Table Brief Introduction of Bristol-Myers Squibb
6. Table Brief Introduction of Pfizer
7. Table Brief Introduction of GlaxoSmithKline
8. Table Brief Introduction of Teva Pharmaceutical
9. Table Brief Introduction of Retrophin
10. Table Brief Introduction of Lumena Pharmaceuticals
11. Table Brief Introduction of Intercept Pharmaceuticals
12. Table Products & Services of Novartis
13. Table Products & Services of Bristol-Myers Squibb
14. Table Products & Services of Pfizer
15. Table Products & Services of GlaxoSmithKline
16. Table Products & Services of Teva Pharmaceutical
17. Table Products & Services of Retrophin
18. Table Products & Services of Lumena Pharmaceuticals
19. Table Products & Services of Intercept Pharmaceuticals
20. Table Market Distribution of Major Players
21. Table Global Major Players Sales Revenue (Million USD) 2017-2020e
22. Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
23. Table Global Primary Biliary Cholangitis Treatment Market Forecast (Million USD) by Region 2021f-2026f
24. Table Global Primary Biliary Cholangitis Treatment Market Forecast (Million USD) Share by Region 2021f-2026f
25. Table Global Primary Biliary Cholangitis Treatment Market Forecast (Million USD) by Demand 2021f-2026f
26. Table Global Primary Biliary Cholangitis Treatment Market Forecast (Million USD) Share by Demand 2021f-2026f

## List Of Figures

### LIST OF FIGURES

1. Figure Global Primary Biliary Cholangitis Treatment Market Size under the Impact of COVID-19, 2017-2021f (USD Million)
2. Figure Global Primary Biliary Cholangitis Treatment Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)
3. Figure Global Primary Biliary Cholangitis Treatment Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)
4. Figure Global Primary Biliary Cholangitis Treatment Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)
5. Figure Global Primary Biliary Cholangitis Treatment Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)
6. Figure Global Primary Biliary Cholangitis Treatment Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)
7. Figure Global Primary Biliary Cholangitis Treatment Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)
8. Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
9. Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
10. Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
11. Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
12. Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
13. Figure Ursodeoxycholic Acid (UDCA) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
14. Figure Obeticholic Acid (Ocaliva) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
15. Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
16. Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
17. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
18. Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

19. Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
20. Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
21. Figure Ursodeoxycholic Acid (UDCA) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
22. Figure Obeticholic Acid (Ocaliva) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
23. Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
24. Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
25. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
26. Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
27. Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
28. Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
29. Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
30. Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
31. Figure Ursodeoxycholic Acid (UDCA) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
32. Figure Obeticholic Acid (Ocaliva) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
33. Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
34. Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
35. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
36. Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
37. Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
38. Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY)

Growth (%) 2018-2021f

39. Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

40. Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

41. Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

42. Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

43. Figure Ursodeoxycholic Acid (UDCA) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

44. Figure Obeticholic Acid (Ocaliva) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

45. Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

46. Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

47. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

48. Figure Brazil Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

49. Figure Argentina Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

50. Figure Rest of Latin America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

51. Figure Ursodeoxycholic Acid (UDCA) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

52. Figure Obeticholic Acid (Ocaliva) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

53. Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

54. Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

55. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

56. Figure GCC Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

57. Figure North Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

58. Figure South Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
59. Figure Rest of Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
60. Figure Ursodeoxycholic Acid (UDCA) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
61. Figure Obeticholic Acid (Ocaliva) Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
62. Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
63. Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
64. Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
65. Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of Novartis 2017-2020e
66. Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of Bristol-Myers Squibb 2017-2020e
67. Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of Pfizer 2017-2020e
68. Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of GlaxoSmithKline 2017-2020e
69. Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of Teva Pharmaceutical 2017-2020e
70. Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of Retrophin 2017-2020e
71. Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of Lumena Pharmaceuticals 2017-2020e
72. Figure Primary Biliary Cholangitis Treatment Sales Revenue (Million USD) of Intercept Pharmaceuticals 2017-2020e
- 73.

## I would like to order

Product name: Primary Biliary Cholangitis Treatment Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Product link: <https://marketpublishers.com/r/PD83E9FAFEC2EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PD83E9FAFEC2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

